echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Luye Pharma Grants Exeltis Exclusive Commercialization Rights for New Drugs in Mexico, Poland

    Luye Pharma Grants Exeltis Exclusive Commercialization Rights for New Drugs in Mexico, Poland

    • Last Update: 2022-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 31, Luye Pharma Group announced that its subsidiary Luye Pharma (Switzerland) entered into an agreement with Exeltis Pharma Mexico, SA de CV and Exeltis Pharmaceuticals Holding, SL (Exeltis) to grant the latter the Mindor Day Transdermal Patch in Lisbon.


    Ristigmine Multi-Day Transdermal Patch is an innovative twice-weekly patch formulation of Ristigmine for the treatment of mild to moderate dementia associated with Alzheimer's disease


    It is reported that the sales of Ristigmine multiday transdermal patch in the European market is the responsibility of the company's local branches and partners; the company also has the exclusive rights to develop and commercialize the product in Japan, as well as the exclusive rights in mainland China.


    Alzheimer's disease is an irreversible neurodegenerative disease that causes progressive decline in memory and other cognitive aspects of patients


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.